ArticleHuman vaccines & immunotherapeutics2026
Incidence of respiratory syncytial virus and influenza: A Danish nationwide cohort study.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is, like influenza, one of the most common causes of severe acute respiratory infections (ARIs) in adults; however, its incidence across different risk and age groups is unknown. We estimated the incidence of registered ARIs in Danish adults, focusing on RSV and contextualizing with influenza. We conducted a nationwide cohort study in Denmark, including all adults aged ≥18 y with a registered ARI, during the 2011/12 to 2022/23 seasons. We estimated the incidence (per 100,000 person-years) of ARI overall and ARI attributable to RSV or influenza, overall and stratified by sex, age, and comorbidity. We identified 962,858 ARIs, of which 10,437 (1.1%) were attributed to RSV and 62,869 (6.5%) to influenza. The ARI incidence increased over time (range: 1,272-2,144), including a rise in RSV incidence (range: 0.2-91.6), while influenza incidence fluctuated (range: 6.7-322.0). In the 2022/23 season, RSV incidence was higher among females, older adults (198.7 in ≥60-y-olds, and 303.2 in ≥75-y-olds), and those with comorbidities, especially hematologic disease (868.6) and chronic obstructive pulmonary disease (679.5). Although influenza incidence was generally higher than RSV, the incidences were comparable for older adults and those with comorbidities. In conclusion, RSV is an important cause of ARIs among adults, comparable to influenza, particularly in older adults and those with comorbidities. These findings underscore the substantial burden of RSV that is relevant for public health planning and clinical decision-making, particularly given the recent approval of three highly effective RSV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.